A randomized, double-blind, active-controlled trial assessing the efficacy and safety of a fixed-dose combination (FDC) of MEtformin hydrochloride 1000 mg ER, SItagliptin phosphate 100 mg, and DApagliflozin propanediol 10 mg in Indian adults with type 2 diabetes: The MESIDA trial
ConclusionFDC of DSM was superior to SM in reducing HbA1c, FPG, and PPG in Indian adults with T2D. Both triple and dual FDCs had optimal safety profiles.
Source: International Journal of Diabetes in Developing Countries - Category: Endocrinology Source Type: research
More News: Dapagliflozin | Diabetes | Diabetes Type 2 | Endocrinology | Fortamet | Forxiga | India Health | Janumet | Januvia | Metformin | Study